Friday, January 18, 2019

Focused Ultrasound-assisted Treatment helps drugs Cross Blood Brain Barrier

Study results of a research team led by scientists at the Massachusetts General Hospital (MGH), Boston, Massachusetts, shows, for the first time, the mechanisms underlying the use of Focused Ultrasound (FUS) to improve the delivery of anti-cancer drugs across the blood brain barrier into brain tumors. The blood–brain/blood–tumor barriers (BBB and BTB) and interstitial transport constitute major obstacles to the...

Phase III ARCHES Trial Shows Positive Results for Enzalutamide in Prostate Cancer

Despite improved treatment options for patients progressing on standard hormone treatment, metastatic prostate cancer still remains a deadly disease. For men with metastatic hormone-sensitive prostate cancer (mHSPC), starting standard androgen deprivation therapy (ADT), the median overall survival (OS) is approximately 45 months. However, for patients with higher-volume disease, the median survival was less (35.1 and 32.2 months, respectively). ADT has long...

Childhood Lymphoma Survivors have Elevated Risk of Solid Cancers

With new and advanced treatments, most children treated for various forms of lymphoma have the opportunity to survive into adulthood.  These patients are, however, at risk, for several possible late adverse effects of their cancer treatment. This risk depends on a number of factors, such as the type of lymphoma, the type and doses of treatments, and the child's age...

Jose Baselga Resigns as Co-Editor-in-Chief of Cancer Discovery

More than 100 days after the New York Times and ProPublica first revealed that Jose Baselga, MD, Ph.D, had failed to disclose millions of dollars in payments from industry, the American Association for Cancer Research (AACR) announced that Baselga, a former society president from 2015-2016, had resigned as one of the editors-in-chief of Cancer Discovery, referred to several times...

Despite Receiving Similar Treatment as White Women, Black Women have Worse Breast Cancer Outcomes

Breast cancer is the most common cancer in women in the United States and worldwide. Furthermore, hormone-receptor–positive, axillary node–negative disease accounts for approximately half of all cases of breast cancer in the United States. Undated study results from the Trial Assigning IndividuaLized Options for TReatment or TAILORx study show that even with equivalent treatments in women with hormone receptor-positive,...

Gilteritinib Available for Prescription in the United States for Adults with Acute Myeloid Leukemia

Gilteritinib (Xospata®; Astellas Pharma) is now available for prescription in the United States for the treatment of adult patients who have relapsed or refractory (resistant to treatment) Acute Myeloid Leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. An oral monotherapy, gilteritinib is the first and only FLT3-targeting agent approved by the U.S. Food and Drug...

Lymph Node Surgery and Axillary Radiotherapy Yield Comparable 10-year Outcome in Breast Cancer

Results from the randomized, Phase III AMAROS clinical trial (NCT00014612),  presented at the San Antonio Breast Cancer Symposium (SABCS), held December 4–8, 2018, in San Antonio, Texas, shows that patients with early-stage breast cancer who had cancer detected in a sentinel lymph node biopsy had comparable 10-year recurrence and survival rates following either axillary radiotherapy or axillary lymph node...

Circulating Tumor Cell Count may Help in Treatment Selection for Metastatic Breast Cancer

Results from the phase III STIC CTC clinical trial, presented at the San Antonio Breast Cancer Symposium (SABCS), held December 4–8, 2018 in San Antonio, Texas, shows that  circulating tumor-cell (CTC) count could be used to choose hormone therapy or chemotherapy as frontline treatment for patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer. CTCs are cells that...

Study Shows Low-Dose Tamoxifen to be Safe and Effective in Reducing Recurrence + New Breast Disease

Data from the randomized, Phase III TAM-01 clinical trial, presented at during the San Antonio Breast Cancer Symposium (SABCS), held December 4–8, 2018 in San Antonio, TX, shows that treatment with a low-dose of tamoxifen (5 mg per day; Nolvadex®; AstraZeneca) halved the risk of disease recurrence and new disease for women who had been treated with surgery following a...

Study Shows Accelerated Partial Breast Irradiation Not Equivalent to Whole Breast Irradiation

Data presented at the San Antonio Breast Cancer Symposium (SABCS), held December 4–8, 2018 in San Antonio, TX, shows that ipsilateral breast tumor recurrence (IBTR) rates 10 years after treatment could not reject the hypothesis that accelerated partial breast irradiation (PBI) after lumpectomy was inferior to whole breast irradiation (WBI). The data is from the NRG (National Surgical Adjuvant Breast...

Related articles